300 related articles for article (PubMed ID: 18714337)
1. Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer.
Musgrove EA; Sergio CM; Loi S; Inman CK; Anderson LR; Alles MC; Pinese M; Caldon CE; Schütte J; Gardiner-Garden M; Ormandy CJ; McArthur G; Butt AJ; Sutherland RL
PLoS One; 2008 Aug; 3(8):e2987. PubMed ID: 18714337
[TBL] [Abstract][Full Text] [Related]
2. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
[TBL] [Abstract][Full Text] [Related]
3. The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.
Butt AJ; Sergio CM; Inman CK; Anderson LR; McNeil CM; Russell AJ; Nousch M; Preiss T; Biankin AV; Sutherland RL; Musgrove EA
Breast Cancer Res; 2008; 10(2):R28. PubMed ID: 18373870
[TBL] [Abstract][Full Text] [Related]
4. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
[TBL] [Abstract][Full Text] [Related]
5. c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells.
Mukherjee S; Conrad SE
J Biol Chem; 2005 May; 280(18):17617-25. PubMed ID: 15757889
[TBL] [Abstract][Full Text] [Related]
6. Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells.
Cheng R; Liu YJ; Cui JW; Yang M; Liu XL; Li P; Wang Z; Zhu LZ; Lu SY; Zou L; Wu XQ; Li YX; Zhou Y; Fang ZY; Wei W
Oncotarget; 2017 May; 8(18):30252-30264. PubMed ID: 28415819
[TBL] [Abstract][Full Text] [Related]
7. Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.
Zhao H; Ou-Yang F; Chen IF; Hou MF; Yuan SS; Chang HL; Lee YC; Plattner R; Waltz SE; Ho SM; Sims J; Wang SC
Neoplasia; 2010 Mar; 12(3):214-23. PubMed ID: 20234815
[TBL] [Abstract][Full Text] [Related]
8. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells.
Kang Y; Cortina R; Perry RR
J Natl Cancer Inst; 1996 Mar; 88(5):279-84. PubMed ID: 8614006
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
[TBL] [Abstract][Full Text] [Related]
10. Identification of downstream targets of estrogen and c-myc in breast cancer cells.
Musgrove EA; Sergio CM; Anderson LR; Inman CK; McNeil CM; Alles MC; Gardiner-Garden M; Ormandy CJ; Butt AJ; Sutherland RL
Adv Exp Med Biol; 2008; 617():445-51. PubMed ID: 18497068
[TBL] [Abstract][Full Text] [Related]
11. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
12. Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
Busch S; Sims AH; Stål O; Fernö M; Landberg G
Cancer Res; 2015 Apr; 75(7):1457-69. PubMed ID: 25833830
[TBL] [Abstract][Full Text] [Related]
13. ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.
Kalyuga M; Gallego-Ortega D; Lee HJ; Roden DL; Cowley MJ; Caldon CE; Stone A; Allerdice SL; Valdes-Mora F; Launchbury R; Statham AL; Armstrong N; Alles MC; Young A; Egger A; Au W; Piggin CL; Evans CJ; Ledger A; Brummer T; Oakes SR; Kaplan W; Gee JM; Nicholson RI; Sutherland RL; Swarbrick A; Naylor MJ; Clark SJ; Carroll JS; Ormandy CJ
PLoS Biol; 2012; 10(12):e1001461. PubMed ID: 23300383
[TBL] [Abstract][Full Text] [Related]
14. Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer.
Roberts CG; Millar EK; O'Toole SA; McNeil CM; Lehrbach GM; Pinese M; Tobelmann P; McCloy RA; Musgrove EA; Sutherland RL; Butt AJ
Oncogene; 2011 Jul; 30(28):3186-97. PubMed ID: 21383694
[TBL] [Abstract][Full Text] [Related]
15. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
16. c-Myc overexpression and endocrine resistance in breast cancer.
McNeil CM; Sergio CM; Anderson LR; Inman CK; Eggleton SA; Murphy NC; Millar EK; Crea P; Kench JG; Alles MC; Gardiner-Garden M; Ormandy CJ; Butt AJ; Henshall SM; Musgrove EA; Sutherland RL
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):147-55. PubMed ID: 17052904
[TBL] [Abstract][Full Text] [Related]
17. EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer.
Katsyv I; Wang M; Song WM; Zhou X; Zhao Y; Park S; Zhu J; Zhang B; Irie HY
Oncotarget; 2016 Oct; 7(43):69592-69605. PubMed ID: 27612429
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer.
Planas-Silva MD; Bruggeman RD; Grenko RT; Smith JS
Exp Mol Pathol; 2007 Feb; 82(1):85-90. PubMed ID: 17046747
[TBL] [Abstract][Full Text] [Related]
19. Alcohol Regulates Genes that Are Associated with Response to Endocrine Therapy and Attenuates the Actions of Tamoxifen in Breast Cancer Cells.
Candelaria NR; Weldon R; Muthusamy S; Nguyen-Vu T; Addanki S; Yoffou PH; Karaboga H; Blessing AM; Bollu LR; Miranda RC; Lin CY
PLoS One; 2015; 10(12):e0145061. PubMed ID: 26661278
[TBL] [Abstract][Full Text] [Related]
20. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
Godinho M; Meijer D; Setyono-Han B; Dorssers LC; van Agthoven T
J Cell Physiol; 2011 Jul; 226(7):1741-9. PubMed ID: 21506106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
